Febuxostat improves outcome in a rat model of cancer cachexia

Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients (NU-FLASH Trial)

(2013) Akira Sezai et al.   CIRCULATION JOURNAL

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure

(2013) Jochen Springer et al.   EUROPEAN HEART JOURNAL

The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy

(2013) Jochen Springer et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats

(2013) Seung Joon Hwang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Long-Term Inhibition of Xanthine Oxidase by Febuxostat Does Not Decrease Blood Pressure in Deoxycorticosterone Acetate (DOCA)-Salt Hypertensive Rats

(2013) Theodora Szasz et al.   PLoS One

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK

(2013) Johji Nomura et al.   PLoS One

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout

(2013) A.-K. Tausche et al.   RHEUMATOLOGY INTERNATIONAL

Cachexia vs obesity: where is the real unmet clinical need?

(2013) Stephan von Haehling et al.   Journal of Cachexia Sarcopenia and Muscle

Cachexia as a major public health problem: frequent, costly, and deadly

(2013) Jerneja Farkas et al.   Journal of Cachexia Sarcopenia and Muscle

Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method

(2013) Stephen A. Stimpson et al.   Journal of Cachexia Sarcopenia and Muscle

Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia

(2012) Jochen Springer et al.   INTERNATIONAL JOURNAL OF CANCER

Research on cachexia, sarcopenia and skeletal muscle in cardiology

(2012) Andrew J. S. Coats   Journal of Cachexia Sarcopenia and Muscle

Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model

(2012) Karsten Lenk et al.   Journal of Cachexia Sarcopenia and Muscle

Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass

(2012) Kunihiro Sakuma et al.   Journal of Cachexia Sarcopenia and Muscle

Molecular and cellular mechanisms of skeletal muscle atrophy: an update

(2012) Alessandro Fanzani et al.   Journal of Cachexia Sarcopenia and Muscle

Febuxostat inhibition of endothelial-bound XO: Implications for targeting vascular ROS production

(2011) Umair Z. Malik et al.   FREE RADICAL BIOLOGY AND MEDICINE

Ursodeoxycholic acid treatment in a rat model of cancer cachexia

(2011) Anika Tschirner et al.   Journal of Cachexia Sarcopenia and Muscle

IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia

(2011) Katja Schmidt et al.   Journal of Cachexia Sarcopenia and Muscle

Akt/protein kinase B in skeletal muscle physiology and pathology

(2010) Miaozong Wu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Cachexia: A new definition

(2008) William J. Evans et al.   CLINICAL NUTRITION

No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure

(2008) Yoshihiro J. Akashi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Xanthine Oxidase Inhibition With Febuxostat Attenuates Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice

(2008) Xin Xu et al.   JOURNAL OF CARDIAC FAILURE